Autopsy report · NCT01531712

Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable

“Due to a low recruitment rate since start of recruitment period.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 11 months after it had already started.
• Ran for about 1 year 10 months before it stopped.
• 6 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Institut Català d'Oncologia

Sponsor type

University, hospital or other

Conditions

Pancreatic Cancer

Interventions

Gemcitabine; Radiotherapy; Tarceva; Oxaliplatin

Participants

6

Sites

1

Countries

Spain

Trials that died the same way

• BicepsTenodesis vs. Biceps Debridement in Combined RC Tears and SLAP Lesions
  “Due to low recruitment rate” (93% match in meaning)
• EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease
  “Due to low recruitment” (88% match in meaning)
• Robotic Therapy and Transcranial Direct Current Stimulation in Patients With Stroke
  “Because of low recruitment rates” (87% match in meaning)
• The Effect of Adherence to Oral Semaglutide on Glycaemic Control in People With Type 2 Diabetes Treated With Metformin
  “Due to recruitment issues.” (85% match in meaning)
• Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
  “Due to Poor Recruitment” (85% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.